Published on
June 17, 2020

New Wave Holdings Corp Appoints Dr. Carolyn Myers As VP Of Commercial Development

Companies Mentioned
No items found.
People Mentioned

TORONTO, June 17, 2020 /PRNewswire/ - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (CSE: SPOR) (Frankfurt: 0XM2) (OTC: TRMND), an investment issuer focused on emerging sectors including the psychedelic sector, is pleased to announce that it has welcomed Dr. Carolyn Myers, Ph.D. to provide business strategy and business development consulting services to the Company.

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care businesses. She is currently Principal of BioEnsemble Ltd, a business strategy consulting firm that advises C-suite executives of small and medium size life sciences companies on a comprehensive range of drug development, commercial and business development services.

Dr. Myers will be instrumental in shaping New Wave's research and development focus in the area of psychedelic compounds, including psilocybin, MDMA, LSD, and ketamine.

"Under Dr. Myers' leadership, New Wave will continue to advance our R&D portfolio with the goal of developing industry partnerships as well as developing and commercializing therapies using psychedelic compounds such as ketamine, psilocybin and MDMA," said Trumbull Fisher, President of New Wave.

About Dr. Carolyn Myers, Ph.D.

Carolyn Myers's is a senior executive with experience optimizing productivity and increasing profitability in the pharmaceutical, biotech and medtech industries. She brings development and commercial expertise across the complete product lifecycle to the team. She also brings a number of key attributes to the Company including a strong ability to develop strategic plans and translate them into actionable plans that have exceeded both objectives and financial goals. She has led the launch of over 20 brand products.  

She completed her BSc., Biology at the University of Waterloo in Waterloo Ontario, a PhD., in Genetics from the University of British Columbia in Vancouver, British Columbia and an Executive MBA from Rutgers University in Newark, New Jersey.

After starting her career with PHARMACIA INC. (acquired by PFIZER, INC.) holding various senior level marketing positions, she spent ~8 years working at the NASDAQ-listed, MYLAN N.V. a global pharmaceutical company that develops, manufactures and markets generic and brand products. MYLAN had worldwide revenue of $5.5B; ~15,000 employees (2010). While at MYLAN she held various positions including Vice President of Brand Business Development and Marketing, President of Mylan Technologies Inc. and President of Dey Laboratories. Her duties included evaluating business development opportunities, executing on long range R&D plans, leading large business units and taking responsibility for P&L performance.

Before starting her own consulting practice, she spent ~7 years working for Allergan PLC, a global pharmaceutical company (NYSE: AGN) focused on developing, manufacturing and commercializing brand pharmaceuticals, devices and biologics in CNS, eye care, medical aesthetics and dermatology, GI, women's health, urology and anti-infectives. Allergan PLC had worldwide revenue of $14.6B, and ~18,000 employees in 2015. At Allergan she held various VP position including Vice President, Global Alliance Management & International Business Development with a focus on expanding product portfolios. This role required her to manage all license/M&A partnerships and lead international business development activities.

Carolyn is a Board Member of Hyloris Pharmaceuticals, an Advisory Board Member of the Centre for Molecular Medicine and Therapeutics, a Steering Committee Member of Mid Atlantic Bio Angels, a Member of Golden Seeds Angels, and a Member of the Licensing Executive Society.


New Wave Holdings Corp. (CSE: SPOR), (FWB: 0XM2), (OTC:TRMND) is an investment issuer focused on the burgeoning psychedelic and esports sectors. In the psychedelic sector, New Wave will focus on active psychedelic compounds, functional mushroom product lines, and develop an IP portfolio focusing on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases.

Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at

Media interested in interviews and more information may contact Brittany Whitmore at

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The securities issued in connection with the Transaction and the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.


Certain statements contained in this news release may constitute forward–looking information, including but not limited to, expansion of operations. Forward–looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward–looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward–looking information. The Company's actual results could differ materially from those anticipated in this forward–looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company's strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward–looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward–looking information should not be unduly relied upon. Any forward–looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward–looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

SOURCE New Wave Holdings Corp.